Analysts’ Viewpoint on Pain Management Therapeutics Market Scenario
Personalization of pain therapies has been led by genetic evaluation tests based on analyzing patient’s deoxyribonucleic acid (DNA) to find appropriate medication for efficient pain management and avoid medicines that could cause severe side-effects. Availability of personalized pain therapies providing more accurate, efficient, and cost-efficient treatment is expected to present significant opportunities for pain management therapeutics market players in the near future. Moreover, several alternative medications with extended release are in development phase for the treatment of chronic and post-operative pain management. Approval of efficient alternative medicines for mild to chronic pain is expected to drive the global pain management therapeutics market size during the forecast period. Furthermore, a broad array of drugs has been developed for the treatment of multiple pain and inflammatory conditions driven by continuous improvement in the biopharmaceutical properties of available drugs.
Treatments for chronic pain are as different as the causes. Milder forms of pain could be relieved by over-the-counter medications such as Tylenol (acetaminophen) or nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, and naproxen. Both acetaminophen and NSAIDs relieve pain caused by muscle aches and stiffness, and additionally, NSAIDs reduce inflammation (swelling and irritation). Topical pain relievers are also available, such as creams, lotions, or sprays, which are applied to the skin in order to relieve pain and inflammation from sore muscles and arthritis.
The number of patients suffering from chronic pain is rising constantly across the globe. According to the Centers for Disease Control and Prevention (CDC), in 2019, 20.4% of adults in the U.S. had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities. According to the European Pain Federation, around 80 million adults in Europe suffer from chronic pain. Increase in incidence rate of cancer across the world contributes to a rise in the demand for pain management therapeutics. This includes pain occurring from cancer therapy as well as from incursion of cancer cells on to bones and other healthy body parts. WHO projections suggest that the global cancer prevalence would increase by around 75% from 2008 to 2030. Therefore, surge in incidence of chronic pain continues to encourage the usage of pain management drugs, which in turn is driving the global market.
Doctors usually prescribe medicines in the initial stages of pain, followed by other treatment options. Prescription drugs are easy and cost-effective without any ambiguity. Moreover, high cost of other alternate pain relief methods such as chiropractics, acupuncture, and acupressure have further driven the prescription drugs market, as cost of one session could equal the cost of complete therapeutic pain relief course for a patient through drugs. Increase in awareness about the availability of medications for pain management propels the consumption and acceptance of pain management drugs over other treatment options. Therefore, high availability, easy access, high awareness, cost effectiveness, and quick relief have made pain management therapeutics more preferable to other treatment options.
In terms of therapeutic, the opioids segment dominated the global market in 2021. Opioids are the most widely prescribed pain management medications to treat moderate to severe chronic pain. Analgesics care in the form of analgesics is provided to cancer patients and treat severe constant pain in patients suffering from terminal illnesses. These are generally administered via subcutaneous, oral, or intramuscular route. Other routes of administration include nasal insufflation, patient-controlled analgesia, and transdermal and oral mucosa routes via lozenges. Opioids can be segmented into three major classes: strong agonists (fentanyl, oxymorphone, and morphine), mild-to-moderate agonists (codeine and hydroxycodone), and opioids with mixed receptor reactions (buprenophrine and pentazocine). The opioids segment has been segregated into oxycodones, hydrocodones, tramadol, and others. The hydrocodones sub-segment led the opioids segment in 2021 due to the introduction and adoption of abuse-deterrent formulations (ADFs).
On the other hand, the NSAIDs (non-steroidal anti-inflammatory drugs) segment is expected to gain pain management therapeutics market share during the forecast period owing to increase in the adoption of NSAIDs to manage mild to moderate pain with proven efficacy and fewer side-effects in the last few decades. Unlike opioids, NSAIDs are not associated with tolerance and dependence, hence the preference for NSAIDs is increasing over other pain management therapeutics.
Based on indication, the cancer pain segment accounted for the largest share of the global pain management therapeutics market in 2021 owing to increasing cases of cancer across the world. Globally, rise in prevalence of cancer is propelling the demand for pain therapeutics in the management of cancer pain. According to International Association of Study of Pain, for the more than 10 million people worldwide who are diagnosed with some form of cancer each year, pain associated with their condition is a serious concern. According to International Agency for Research on Cancer (IARC) estimates, 17.0 million new cancer cases and 9.5 million cancer deaths were reported globally in 2018. By 2040, the global burden is expected to rise to 27.5 million new cancer cases and 16.3 million cancer deaths due to increase in the geriatric population.
As per pain management therapeutics market forecast, the chronic back pain segment is likely to gain market share during the forecast period due to rise in prevalence of chronic low back pain. Nearly 65 million people in the U.S. report an episode of back pain. Some 16 million adults (8%) experience persistent or chronic back pain, and as a result are limited in certain everyday activities. Lower back pain affects an estimated 540 million people across the globe. More than one in ten suffer from lower back pain.
North America is expected to account for the largest share of the global pain management therapeutics market during the forecast period. This is ascribed to improved healthcare policies, changes in lifestyle, advancement in healthcare facilities, and availability of effective and convenient treatment options in the U.S. and Canada.
The market in Asia Pacific is likely to grow at a rapid pace in the next few years. Developing countries in the region such as Japan, China, and India are expected to contribute to the rise in demand for therapeutic pain management therapeutics, increase in awareness, and early availability of pain management therapeutic products.
The pain management therapeutics market report concludes with the company profiles section that includes key information about major players in the market. Key players are focusing on product launches, mergers & acquisitions, partnerships, and collaborations to enhance their pain management therapeutics market share. Abbott, AstraZeneca plc, Pfizer, Inc., Depomed, Inc. Endo International plc, GlaxoSmithKline plc, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Novartis AG, Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd., Venus Remedies Limited, and Q Biomed, Inc. are the prominent players operating in the global market.
Each of these players has been profiled in the pain management therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 73.6 Bn |
|
Market Forecast Value in 2031 |
More than US$ 98.0 Bn |
|
Compound Annual Growth Rate (CAGR) |
2.9% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global pain management therapeutics market was valued at US$ 73.6 Bn in 2021.
The global market is projected to reach more than US$ 98.0 Bn by 2031.
The global pain management therapeutics market is anticipated to grow at a CAGR of 2.9% from 2022 to 2031.
Increase in incidence of chronic pain disorders is driving the global market.
Abbott, AstraZeneca plc, Pfizer, Inc., Depomed, Inc. Endo International plc, GlaxoSmithKline plc, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Novartis AG, Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd., Venus Remedies Limited, and Q Biomed, Inc. are the prominent players oerating in the global market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pain Management Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Therapeutics Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pain Management Therapeutics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Mergers & Acquisitions
5.3. Covid 19 Impact Analysis
6. Global Pain Management Therapeutics Market Analysis and Forecast, by Therapeutic
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapeutic, 2017–2031
6.3.1. Anticonvulsants
6.3.2. Antidepressants
6.3.3. Anesthetics
6.3.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
6.3.5. Opioids
6.3.6. Other Non-narcotic Analgesic
6.3.7. Antimigraine Agents
6.4. Market Attractiveness Analysis, by Therapeutic
7. Global Pain Management Therapeutics Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Neuropathic Pain
7.3.2. Fibromyalgia
7.3.3. Arthritic Pain
7.3.4. Chronic Back Pain
7.3.5. Migraine
7.3.6. Post-operative Pain
7.3.7. Cancer Pain
7.4. Market Attractiveness Analysis, by Indication
8. Global Pain Management Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Oral
8.3.2. Parenteral
8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Pain Management Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Retail Pharmacies
9.3.2. Online Pharmacies
9.3.3. Others
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Pain Management Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Pain Management Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapeutic, 2017–2031
11.2.1. Anticonvulsants
11.2.2. Antidepressants
11.2.3. Anesthetics
11.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
11.2.5. Opioids
11.2.6. Other Non-narcotic Analgesic
11.2.7. Antimigraine Agents
11.3. Market Value Forecast, by Indication, 2017–2031
11.3.1. Neuropathic Pain
11.3.2. Fibromyalgia
11.3.3. Arthritic Pain
11.3.4. Chronic Back Pain
11.3.5. Migraine
11.3.6. Post-operative Pain
11.3.7. Cancer Pain
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Parenteral
11.4.3. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Retail Pharmacies
11.5.2. Online Pharmacies
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Therapeutic
11.7.2. By Indication
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Pain Management Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapeutic, 2017–2031
12.2.1. Anticonvulsants
12.2.2. Antidepressants
12.2.3. Anesthetics
12.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
12.2.5. Opioids
12.2.6. Other Non-narcotic Analgesic
12.2.7. Antimigraine Agents
12.3. Market Value Forecast, by Indication, 2017–2031
12.3.1. Neuropathic Pain
12.3.2. Fibromyalgia
12.3.3. Arthritic Pain
12.3.4. Chronic Back Pain
12.3.5. Migraine
12.3.6. Post-operative Pain
12.3.7. Cancer Pain
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Retail Pharmacies
12.5.2. Online Pharmacies
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Therapeutic
12.7.2. By Indication
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Pain Management Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapeutic, 2017–2031
13.2.1. Anticonvulsants
13.2.2. Antidepressants
13.2.3. Anesthetics
13.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
13.2.5. Opioids
13.2.6. Other Non-narcotic Analgesic
13.2.7. Antimigraine Agents
13.3. Market Value Forecast, by Indication, 2017–2031
13.3.1. Neuropathic Pain
13.3.2. Fibromyalgia
13.3.3. Arthritic Pain
13.3.4. Chronic Back Pain
13.3.5. Migraine
13.3.6. Post-operative Pain
13.3.7. Cancer Pain
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Retail Pharmacies
13.5.2. Online Pharmacies
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Therapeutic
13.7.2. By Indication
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Pain Management Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapeutic, 2017–2031
14.2.1. Anticonvulsants
14.2.2. Antidepressants
14.2.3. Anesthetics
14.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
14.2.5. Opioids
14.2.6. Other Non-narcotic Analgesic
14.2.7. Antimigraine Agents
14.3. Market Value Forecast, by Indication, 2017–2031
14.3.1. Neuropathic Pain
14.3.2. Fibromyalgia
14.3.3. Arthritic Pain
14.3.4. Chronic Back Pain
14.3.5. Migraine
14.3.6. Post-operative Pain
14.3.7. Cancer Pain
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Retail Pharmacies
14.5.2. Online Pharmacies
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Therapeutic
14.7.2. By Indication
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Pain Management Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Therapeutic, 2017–2031
15.2.1. Anticonvulsants
15.2.2. Antidepressants
15.2.3. Anesthetics
15.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
15.2.5. Opioids
15.2.6. Other Non-narcotic Analgesic
15.2.7. Antimigraine Agents
15.3. Market Value Forecast, by Indication, 2017–2031
15.3.1. Neuropathic Pain
15.3.2. Fibromyalgia
15.3.3. Arthritic Pain
15.3.4. Chronic Back Pain
15.3.5. Migraine
15.3.6. Post-operative Pain
15.3.7. Cancer Pain
15.4. Market Value Forecast, by Route of Administration, 2017–2031
15.4.1. Oral
15.4.2. Parenteral
15.4.3. Others
15.5. Market Value Forecast, by Distribution Channel, 2017–2031
15.5.1. Retail Pharmacies
15.5.2. Online Pharmacies
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Therapeutic
15.7.2. By Indication
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Financial Analysis
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. AstraZeneca plc
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Financial Analysis
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. Pfizer, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Financial Analysis
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Depomed, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Financial Analysis
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Endo International plc
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Financial Analysis
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. GlaxoSmithKline plc
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Financial Analysis
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. Johnson & Johnson Services, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Financial Analysis
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Mallinckrodt Pharmaceuticals
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Financial Analysis
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
16.3.9. Merck & Co., Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Financial Analysis
16.3.9.3. Growth Strategies
16.3.9.4. SWOT Analysis
16.3.10. Novartis AG
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Financial Analysis
16.3.10.3. Growth Strategies
16.3.10.4. SWOT Analysis
16.3.11. Purdue Pharma L.P.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Financial Analysis
16.3.11.3. Growth Strategies
16.3.11.4. SWOT Analysis
16.3.12. Teva Pharmaceutical Industries Ltd
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Financial Analysis
16.3.12.3. Growth Strategies
16.3.12.4. SWOT Analysis
16.3.13. Venus Remedies Limited
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Financial Analysis
16.3.13.3. Growth Strategies
16.3.13.4. SWOT Analysis
16.3.14. Q Biomed, Inc.
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Financial Analysis
16.3.14.3. Growth Strategies
16.3.14.4. SWOT Analysis
List of Tables
Table 01: Global Pain Management Therapeutics Market Value Share, by Therapeutic, 2021
Table 02: Global Pain Management Therapeutics Market Value Share, by Indication, 2021
Table 03: Global Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Therapeutic, 2017–2031
Table 04: Global Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 05: Global Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 06: Global Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 07: Global Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 08: North America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Therapeutic, 2017–2031
Table 09: North America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 10: North America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 11: North America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: North America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 13: Europe Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Therapeutic, 2017–2031
Table 14: Europe Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 15: Europe Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 16: Europe Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Europe Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Asia Pacific Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Therapeutic, 2017–2031
Table 19: Asia Pacific Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 20: Asia Pacific Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 21: Asia Pacific Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 22: Asia Pacific Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 23: Latin America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Therapeutic, 2017–2031
Table 24: Latin America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 25: Latin America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 26: Latin America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 27: Latin America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 28: Middle East & Africa Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Therapeutic, 2017–2031
Table 29: Middle East & Africa Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 30: Middle East & Africa Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 31: Middle East & Africa Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 32: Middle East & Africa Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Pain Management Therapeutics Market Snapshot
Figure 02: Global Pain Management Therapeutics Market Segments With Leading Market Share (%), 2021
Figure 03: Key Industry Developments (Pain Management Therapeutics Market)
Figure 04: Global Pain Management Therapeutics Market Value (US$ Mn) Forecast, 2017‒2031
Figure 05: Global Pain Management Therapeutics Market Value Share (%), by Therapeutic (2021)
Figure 06: Global Pain Management Therapeutics Market Value Share (%), by Indication (2021)
Figure 07: Global Pain Management Therapeutics Market Value Share (%), by Route of Administration (2021)
Figure 08: Global Pain Management Therapeutics Market Value Share(%), by Distribution Channel (2021)
Figure 09: Global Pain Management Therapeutics Market Value Share (%), by Region (2021)
Figure 10: Global Pain Management Therapeutics Market Value Share Analysis, by Therapeutic, 2021 and 2031
Figure 11: Global Pain Management Therapeutics Market Attractiveness Analysis, by Therapeutic, 2022–2031
Figure 12: Global Pain Management Therapeutics Market Value Share Analysis, by Indication, 2021 and 2031
Figure 13: Global Pain Management Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031
Figure 14: Global Pain Management Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 15: Global Pain Management Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 16: Global Pain Management Therapeutics Market Value Share(%), by Distribution Channel, 2021 and 2031
Figure 17: Global Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 18: Global Pain Management Therapeutics Market Value Share Analysis, by Region 2021 and 2031
Figure 19: Global Pain Management Therapeutics Market Attractiveness Analysis, by Region, 2022–2031
Figure 20: North America Pain Management Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 21: North America Pain Management Therapeutics Market Value Share (%), by Therapeutic, 2021 and 2031
Figure 22: North America Pain Management Therapeutics Market Attractiveness Analysis, by Therapeutic, 2022–2031
Figure 23: North America Pain Management Therapeutics Market Value Share (%), by Indication, 2021 and 2031
Figure 24: North America Pain Management Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031
Figure 25: North America Pain Management Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
Figure 26: North America Pain Management Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 27: North America Pain Management Therapeutics Market Share (%), by Distribution Channel, 2021 and 2031
Figure 28: North America Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 29: North America Pain Management Therapeutics Market Value Share (%), by Country, 2021 and 2031
Figure 30: North America Pain Management Therapeutics Market Attractiveness Analysis, by Country, 2022–2031
Figure 31: Europe Pain Management Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 32: Europe Pain Management Therapeutics Market Value Share (%), by Therapeutic, 2021 and 2031
Figure 33: Europe Pain Management Therapeutics Market Attractiveness Analysis, by Therapeutic, 2022–2031
Figure 34: Europe Pain Management Therapeutics Market Value Share (%), by Indication, 2021 and 2031
Figure 35: Europe Pain Management Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031
Figure 36: Europe Pain Management Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
Figure 37: Europe Pain Management Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 38: Europe Pain Management Therapeutics Market Share (%), by Distribution Channel, 2021 and 2031
Figure 39: Europe Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 40: Europe Pain Management Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 41: Europe Pain Management Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 42: Asia Pacific Pain Management Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 43: Asia Pacific Pain Management Therapeutics Market Value Share (%), by Therapeutic, 2021 and 2031
Figure 44: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, by Therapeutic, 2022–2031
Figure 45: Asia Pacific Pain Management Therapeutics Market Value Share (%), by Indication, 2021 and 2031
Figure 46: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031
Figure 47: Asia Pacific Pain Management Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
Figure 48: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 49: Asia Pacific Pain Management Therapeutics Market Share (%), by Distribution Channel, 2021 and 2031
Figure 50: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 51: Asia Pacific Pain Management Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 52: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 53: Latin America Pain Management Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 54: Latin America Pain Management Therapeutics Market Value Share (%), by Therapeutic, 2021 and 2031
Figure 55: Latin America Pain Management Therapeutics Market Attractiveness Analysis, by Therapeutic, 2022–2031
Figure 56: Latin America Pain Management Therapeutics Market Value Share (%), by Indication, 2021 and 2031
Figure 57: Latin America Pain Management Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031
Figure 58: Latin America Pain Management Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
Figure 59: Latin America Pain Management Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 60: Latin America Pain Management Therapeutics Market Share (%), by Distribution Channel, 2021 and 2031
Figure 61: Latin America Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 62: Latin America Pain Management Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 63: Latin America Pain Management Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 64: Middle East & Africa Pain Management Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 65: Middle East & Africa Pain Management Therapeutics Market Value Share (%), by Therapeutic, 2021 and 2031
Figure 66: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, by Therapeutic, 2022–2031
Figure 67: Middle East & Africa Pain Management Therapeutics Market Value Share (%), by Indication, 2021 and 2031
Figure 68: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031
Figure 69: Middle East & Africa Pain Management Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
Figure 70: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 71: Middle East & Africa Pain Management Therapeutics Market Share (%), by Distribution Channel, 2021 and 2031
Figure 72: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 73: Middle East & Africa Pain Management Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 74: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pain Management Therapeutics Market
